Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

September 22, 2020September 22, 2020

CHMP Favors Zejula as First-line Maintenance Therapy for Platinum-sensitive Advanced Ovarian Cancer

News

The Committee for Medicinal Products for Human Use (CHMP) has recommended Zejula (niraparib) as a first-line maintenance therapy for women with advanced ovarian cancer who responded to platinum-based chemotherapy. This favorable opinion ... Read more

September 3, 2020September 3, 2020

Research Alliance Hopes to Raise $200K During Awareness Month

News

The Ovarian Cancer Research Alliance (OCRA) is hoping to raise $200,000 in this year’s awareness month campaign to help fund research and support those with the disease, the organization announced. ... Read more

August 13, 2020August 13, 2020

XMT-1536 on FDA Fast Track for Platinum-resistant, Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has given fast track designation to Mersana Therapeutics’ XMT-1536 as a possible treatment for women with platinum-resistant high-grade serous ovarian cancer who received up to three prior lines ... Read more

August 4, 2020August 4, 2020

Study: Tests Used to Predict Response to PARP Inhibitors Yield Inconsistent Result

News

Tests used in clinical trials of ovarian cancer to determine if tumors lack the ability to repair their DNA — a status termed “homologous recombination deficiency” (HRD), and likely would ... Read more

July 23, 2020July 23, 2020

PARP Inhibitor Pamiparib Under Review in China to Treat Advanced Ovarian Cancer

News

China’s regulatory agency has agreed to consider a request that pamiparib, BeiGene‘s investigational PARP inhibitor, be approved to treat people with advanced ovarian cancers after at least two prior lines of chemotherapy. ... Read more

July 7, 2020July 7, 2020

3D-PREDICT Trial Tests Kiyatec’s Predictor of Treatment Responses in Ovarian Cancer Patients

News

An ongoing observational registry study is evaluating Kiyatec‘s novel technology, in which a patient’s own tumor tissue is cultured in a lab dish and exposed to different therapies as a ... Read more

June 23, 2020June 23, 2020

Protein Biomarkers to Gauge Cancer Response to Chemo Identified

News

Investigators using targeted proteomics — a technique to detect proteins of interest — on samples of ovarian cancer found a wide variety of biomarkers that might help predict which chemotherapies patients are more ... Read more

June 18, 2020June 18, 2020

Mirvetuximab Soravtansine-Avastin Combo Linked to Promising Responses

News

When given alongside Avastin (bevacizumab), mirvetuximab soravtansine leads to promising treatment responses in women with recurrent ovarian cancer — particularly those whose tumors contain high levels of the protein folate ... Read more

June 4, 2020June 4, 2020

Genetic Testing for Breast, Ovarian Cancer Risk Safely Done at Home, Trial Shows

News

Genetic tests to assess the risk of breast and ovarian cancer can be performed remotely in the safety of the patients’ homes, according to data from an early Phase 1 ... Read more

June 2, 2020June 2, 2020

Breastfeeding Lowers Risk of Ovarian Cancer for Decades, Study Finds

News

Women who breastfeed are at a significantly lower risk of developing ovarian cancer overall and some of its subtypes, including the deadliest — high-grade serous tumors, a large data study reported. ... Read more